News
Acquisition · Consumer Goods · Kenvue · Kimberly-Clark
Kimberly-Clark acquired Tylenol-maker Kenvue in a cash and stock transaction valued at $21.01 per share, providing Kenvue shareholders $6.8 billion in upfront cash, which immediately caused Kimberly-Clark shares to plunge over 15% premarket on Monday.
This acquisition creates a global health and wellness leader with projected 2025 net revenue of $32 billion and $7 billion adjusted EBITDA, adding iconic consumer brands to Kimberly-Clark's portfolio. Kenvue shareholders receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share.
The merger targets $1.9 billion in cost synergies and $500 million in incremental revenue synergies, partly offset by $300 million in reinvestment, requiring $2.5 billion in cash costs to achieve these benefits.
